These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28489605)

  • 21. Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays.
    Caprini E; Cristofoletti C; Arcelli D; Fadda P; Citterich MH; Sampogna F; Magrelli A; Censi F; Torreri P; Frontani M; Scala E; Picchio MC; Temperani P; Monopoli A; Lombardo GA; Taruscio D; Narducci MG; Russo G
    Cancer Res; 2009 Nov; 69(21):8438-46. PubMed ID: 19843862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
    Woollard WJ; Pullabhatla V; Lorenc A; Patel VM; Butler RM; Bayega A; Begum N; Bakr F; Dedhia K; Fisher J; Aguilar-Duran S; Flanagan C; Ghasemi AA; Hoffmann RM; Castillo-Mosquera N; Nuttall EA; Paul A; Roberts CA; Solomonidis EG; Tarrant R; Yoxall A; Beyers CZ; Ferreira S; Tosi I; Simpson MA; de Rinaldis E; Mitchell TJ; Whittaker SJ
    Blood; 2016 Jun; 127(26):3387-97. PubMed ID: 27121473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    Kim EJ; Lewis DJ; Duvic M
    J Invest Dermatol; 2017 Sep; 137(9):1831-1833. PubMed ID: 28843295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
    Mitani Y; Liu B; Rao PH; Borra VJ; Zafereo M; Weber RS; Kies M; Lozano G; Futreal PA; Caulin C; El-Naggar AK
    Clin Cancer Res; 2016 Feb; 22(3):725-33. PubMed ID: 26631609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome.
    Cristofoletti C; Bresin A; Caprini E; Russo G; Narducci MG
    Cell Cycle; 2019 Jun; 18(11):1292-1294. PubMed ID: 31106661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
    Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
    Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
    Ungewickell A; Bhaduri A; Rios E; Reuter J; Lee CS; Mah A; Zehnder A; Ohgami R; Kulkarni S; Armstrong R; Weng WK; Gratzinger D; Tavallaee M; Rook A; Snyder M; Kim Y; Khavari PA
    Nat Genet; 2015 Sep; 47(9):1056-60. PubMed ID: 26258847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation.
    Jones CL; Wain EM; Chu CC; Tosi I; Foster R; McKenzie RC; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2010 Apr; 130(4):1116-25. PubMed ID: 19759548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
    Booken N; Gratchev A; Utikal J; Weiss C; Yu X; Qadoumi M; Schmuth M; Sepp N; Nashan D; Rass K; Tüting T; Assaf C; Dippel E; Stadler R; Klemke CD; Goerdt S
    Leukemia; 2008 Feb; 22(2):393-9. PubMed ID: 18033314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clonal nature of circulating Sezary cells.
    Weinberg JM; Jaworsky C; Benoit BM; Telegan B; Rook AH; Lessin SR
    Blood; 1995 Dec; 86(11):4257-62. PubMed ID: 7492785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.
    Andersson E; Eldfors S; Edgren H; Ellonen P; Väkevä L; Ranki A; Mustjoki S
    Exp Dermatol; 2014 May; 23(5):366-8. PubMed ID: 24689486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.
    Braun FC; Grabarczyk P; Möbs M; Braun FK; Eberle J; Beyer M; Sterry W; Busse F; Schröder J; Delin M; Przybylski GK; Schmidt CA
    Leukemia; 2011 Sep; 25(9):1494-501. PubMed ID: 21625233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of cloning rearrangement of T-cell receptor gamma gene in primary cutaneous lymphoma].
    Pawlaczyk M; Kistowska M; Poreba E; Filas V; Breborowicz J; Goździcka-Józefiak A
    Pol Merkur Lekarski; 2003 Nov; 15(89):420-3. PubMed ID: 14969134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TOX expression in different subtypes of cutaneous lymphoma.
    Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic alterations in Sezary syndrome.
    Iżykowska K; Przybylski GK
    Leuk Lymphoma; 2011 May; 52(5):745-53. PubMed ID: 21323514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycosis fungoides and Sézary syndrome.
    Espinet B; Salgado R
    Methods Mol Biol; 2013; 973():175-88. PubMed ID: 23412790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers.
    van Doorn R; Slieker RC; Boonk SE; Zoutman WH; Goeman JJ; Bagot M; Michel L; Tensen CP; Willemze R; Heijmans BT; Vermeer MH
    J Invest Dermatol; 2016 Sep; 136(9):1876-1884. PubMed ID: 27113428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome.
    Brito-Babapulle V; Hamoudi R; Matutes E; Watson S; Kaczmarek P; Maljaie H; Catovsky D
    Br J Haematol; 2000 Jul; 110(1):180-7. PubMed ID: 10930996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.